ArticleFrontiers in endocrinology2023
Tocilizumab for the fifth progression of cystic childhood craniopharyngioma-a case report.
Article in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- Modern treatment of craniopharyngioma to improve outcomes: evidence of a change of paradigm.Endocrine · 2025Pooled it
- Advancing Craniopharyngioma Management: A Systematic Review of Current Targeted Therapies and Future Perspectives.International journal of molecular sciences · 2024Pooled it
- Spatially Resolved Multiomics Reveals Metabolic Remodeling and Autophagy Activation in Adamantinomatous Craniopharyngiomas.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Systemic Molecularly Targeted Therapies for Neoadjuvant and Salvage Craniopharyngioma: A Contemporary Narrative Review.Biomedicines · 2026Review
- Management of Acquired Hypothalamic Dysfunction and the Hypothalamic Syndrome; It Is More Than Obesity.Endocrine reviews · 2025Review
- Intratumoral tocilizumab in children with cystic craniopharyngiomas: targeted therapy.Journal of neuro-oncology · 2025Article
- Molecular subtypes of adamantinomatous craniopharyngiomas.Neuro-oncology · 2025Review
- Current clinical trials for craniopharyngiomas: what's on the horizon?Journal of neuro-oncology · 2025Review
- Advances in the Management of Craniopharyngioma: A Narrative Review of Recent Developments and Clinical Strategies.Journal of clinical medicine · 2025Review
- Recurrent adamantinomatous craniopharyngioma stabilized with tocilizumab and bevacizumab: illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- A case-based review of adult-onset craniopharyngioma.Frontiers in endocrinology · 2025Review
- Recent advances in craniopharyngioma pathophysiology and emerging therapeutic approaches.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present the case of a 15-year-old girl, with a fifth cystic progression of an adamantinomatous craniopharyngioma after multiple surgeries and previous local radiotherapy. She had severe visual impairment, panhypopituitarism including diabetes insipidus, and several components of hypothalamic damage, including morbid obesity and severe fatigue. To prevent further late effects hampering her quality of survival, she was treated biweekly with intravenous tocilizumab, an anti-interleukin-6 agent, which stabilized the cyst for a prolonged time. Based on the biology of adamantinomatous craniopharyngioma, this immune-modulating treatment seems promising for the treatment of this cystic tumor in order to reduce surgery and delay or omit radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.